hydrocortisone plus fludrocortisone
Phase 3Small molecule
hydrocortisone plus fludrocortisone is one of 61 small molecule programs targeting Cardiac Surgery. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glypressin
MMallinckrodt
Approved
Pitressin
AAultman Health Foundation
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Zocor
OOrganon and Co
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapiblyk
AAultman Health Foundation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Surgery1 trial
Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery
Not yet recruiting·—·Phase 3·NCT07037043·196 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details